Literature DB >> 22669568

Acute, generalised but transient muscle cramping and weakness shortly after first oxaliplatin infusion.

Elisabeth Krexner, Anika Stickler, Christian Prainer, Josef Finsterer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22669568     DOI： 10.1007/s12032-012-0264-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  10 in total

1.  [Gitelman syndrome associated with chondrocalcinosis: description of two cases].

Authors:  M Gutierrez; F Silveri; C Bertolazzi; G Giacchetti; M Tardella; L Di Geso; E Filippucci; W Grassi
Journal:  Reumatismo       Date:  2010 Jan-Mar

2.  Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.

Authors:  J P Durand; G Deplanque; V Montheil; J M Gornet; F Scotte; O Mir; A Cessot; R Coriat; E Raymond; E Mitry; P Herait; Y Yataghene; F Goldwasser
Journal:  Ann Oncol       Date:  2011-03-22       Impact factor: 32.976

3.  Reversible palpebral ptosis following oxaliplatin infusion.

Authors:  N La Verde; M C Garassino; G Spinelli; A Scanni; P Sburlati; G Farina; R Labianca
Journal:  Dig Liver Dis       Date:  2007-10-29       Impact factor: 4.088

4.  Acute oxaliplatin-induced peripheral nerve hyperexcitability.

Authors:  Richard H Wilson; Tanya Lehky; Rebecca R Thomas; Mary G Quinn; Mary Kay Floeter; Jean L Grem
Journal:  J Clin Oncol       Date:  2002-04-01       Impact factor: 44.544

5.  Betamethasone-induced hypokalemic periodic paralysis in pregnancy.

Authors:  Corey M Teagarden; Carla W Picardo
Journal:  Obstet Gynecol       Date:  2011-02       Impact factor: 7.661

6.  High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.

Authors:  Yasuhiro Kidera; Taroh Satoh; Shinya Ueda; Wataru Okamoto; Isamu Okamoto; Soichi Fumita; Kimio Yonesaka; Hidetoshi Hayashi; Chihiro Makimura; Kunio Okamoto; Hidemi Kiyota; Junji Tsurutani; Masaki Miyazaki; Masahiro Yoshinaga; Kimiko Fujiwara; Yuzuru Yamazoe; Kenzo Moriyama; Masanobu Tsubaki; Yasutaka Chiba; Shozo Nishida; Kazuhiko Nakagawa
Journal:  Int J Clin Oncol       Date:  2011-01-18       Impact factor: 3.402

7.  Blepharoptosis following oxaliplatin administration.

Authors:  S Cecilia Lau; Stephen I Shibata
Journal:  J Oncol Pharm Pract       Date:  2009-12       Impact factor: 1.809

8.  Oxaliplatin-induced hyperexcitability syndrome in a patient with pancreatic cancer.

Authors:  Hamid Saadati; Muhammad Wasif Saif
Journal:  JOP       Date:  2009-07-06

9.  Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer.

Authors:  Muhammad Wasif Saif; Shahrukh Hashmi
Journal:  Cancer Chemother Pharmacol       Date:  2007-09-12       Impact factor: 3.333

10.  Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy.

Authors:  T J Lehky; G D Leonard; R H Wilson; J L Grem; M K Floeter
Journal:  Muscle Nerve       Date:  2004-03       Impact factor: 3.217
  10 in total
  3 in total

1.  Severe Generalized Weakness, Paralysis, and Aphasia following Administration of Irinotecan and Oxaliplatin during FOLFIRINOX Chemotherapy.

Authors:  Manisha Chandar; Robert de Wilton Marsh
Journal:  Case Rep Oncol       Date:  2015-03-04

Review 2.  Pancreatic cancer and FOLFIRINOX: a new era and new questions.

Authors:  Robert De W Marsh; Mark S Talamonti; Matthew Harold Katz; Joseph M Herman
Journal:  Cancer Med       Date:  2015-02-19       Impact factor: 4.452

3.  Management of orphan symptoms: ESMO Clinical Practice Guidelines for diagnosis and treatment†.

Authors:  D Santini; G Armento; R Giusti; M Ferrara; C Moro; F Fulfaro; P Bossi; F Arena; C I Ripamonti
Journal:  ESMO Open       Date:  2020-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.